Browsing Category
Pharma Industry News
4724 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Why CVS Health Corporation’s TrumpRx discount card move is unsettling the drug pricing status quo
CVS Health Corporation begins accepting TrumpRx discount cards, reshaping pharmacy pricing dynamics. Find out what this means for drug costs and investors.
From AI to weight loss drugs, what Super Bowl LX ads reveal about the next legitimacy war
Super Bowl LX ads from AI platforms and GLP-1 drugmakers reveal how trust, not technology, is shaping the next growth cycle. Read the full analysis.
Is mutant-selective JAK2 inhibition ready for clinical reality after Prelude Therapeutics’ FDA IND clearance?
Prelude Therapeutics gains FDA IND clearance for PRT12396. Read how mutant-selective JAK2 inhibition could reshape MPN drug development.
Can oral NMDA blockers like Ketamir-2 disrupt current off-label CIPN treatments?
Find out how MIRA Pharmaceuticals’ Ketamir-2 aims to disrupt CIPN care with oral NMDA therapy as the company targets Fast Track and prepares for Phase 2a trials.
How SC-dosed NK cell engagers like GTB-5550 could disrupt cancer care delivery models
GT Biopharma’s GTB-5550 receives FDA clearance with subcutaneous delivery. See how this trial could shift NK immunotherapy into outpatient cancer care.
Is co-administered COVID prophylaxis with antibodies and mRNA vaccines the next FDA-backed model?
Invivyd’s LIBERTY trial explores co-administered COVID prevention with VYD2311 and mRNA vaccines. See how this could influence FDA and payer strategies.
Is viral vector therapy finally gaining traction in chemotherapy-resistant pediatric tumors?
Theriva’s APAO 2026 data shows viral–chemotherapy synergy in eye tumors. Find out what VCN-01 signals for pediatric oncology's biologics future.
Eisai and Shanghai Henlius Biotech enter Japan-focused licensing pact for serplulimab as PD-1 competition tightens
Discover how Eisai Co., Ltd.’s serplulimab licensing deal with Henlius could reshape Japan’s PD-1 oncology market and investor expectations.
Akeso secures fifth NMPA breakthrough therapy designation for ivonescimab, sharpening its first-line oncology ambitions in China
Akeso Inc. secures a fifth breakthrough therapy designation for ivonescimab. Find out why this matters for oncology strategy and investors.
Neuren Pharmaceuticals (ASX: NEU) begins first-ever Phase 3 trial in Phelan-McDermid syndrome
Neuren Pharmaceuticals Limited has dosed the first patient in the first Phase 3 Phelan-McDermid syndrome trial. See why it matters for rare disease drug development.